Prediction of Pneumococcal Conjugate Vaccine Effectiveness against Invasive Pneumococcal Disease Using Opsonophagocytic Activity and Antibody Concentrations Determined by Enzyme-Linked Immunosorbent Assay with 22F Adsorption

被引：36

作者：

Schuerman, L. ^{[1
]}

Wysocki, J. ^{[2
,3
]}

Tejedor, J. C. ^{[4
]}

Knuf, M. ^{[5
,6
]}

Kim, K. -H. ^{[7
]}

Poolman, J. ^{[1
]}

机构：

[1] GlaxoSmithKline Biol, Wavre Rixensart, Belgium

[2] Univ Sch Med Sci, Poznan, Poland

[3] Reg Med Ctr Mother & Child, Poznan, Poland

[4] Hosp Mostoles, Serv Neonatol, Madrid, Spain

[5] Johannes Gutenberg Univ Mainz, Zentrum Kinder & Jugendmed, Mainz, Germany

[6] Childrens Hosp, Dr Horst Schmidt Klin, Wiesbaden, Germany

[7] Ewha Womans Univ, Dept Pediat, Coll Med, Seoul, South Korea

来源：

CLINICAL AND VACCINE IMMUNOLOGY | 2011年 / 18卷 / 12期

关键词：

SEROTYPE; 19A; PHID-CV; UNITED-STATES; IMMUNOGENICITY; CHILDREN; EFFICACY; SAFETY; PROTECTION; SCHEDULE; INFANTS;

D O I：

10.1128/CVI.05313-11

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We compared the abilities of two serological readouts, antipolysaccharide IgG antibody concentrations and opsonophagocytic activity (OPA) titers, to predict the clinical effectiveness of the 7-valent pneumococcal conjugate vaccine (7vCRM) against invasive pneumococcal disease (IPD). We also assessed the accuracy of the previously established thresholds for GlaxoSmithKline's enzyme-linked immunosorbent assay with 22F adsorption (22F-ELISA) (>= 0.2 mu g/ml) and OPA assay (titer, >= 8) in predicting effectiveness. We showed that following a 3-dose 7vCRM primary vaccination, the serological response rates as determined using thresholds of >= 0.2 mu g/ml IgG and an OPA titer of >= 8 corresponded well with overall effectiveness against IPD. In addition, the OPA assay seemed to better predict serotype-specific effectiveness than enzyme-linked immunoassay. Finally, when applied to post-dose-2 immune responses, both thresholds also corresponded well with the overall IPD effectiveness following a 2-dose 7vCRM primary vaccination. These results support the importance of the OPA assay in evaluating immune responses to pneumococcal conjugate vaccines.

引用

页码：2161 / 2167

页数：7

共 46 条

[41] Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study [J].

Whitney, Cynthia G. ;

Pilishvili, Tamor ;

Farley, Monica M. ;

Schaffner, William ;

Craig, Allen S. ;

Lynfield, Ruth ;

Nyquist, Ann-Christine ;

Gershman, Kenneth A. ;

Vazquez, Marietta ;

Bennett, Nancy M. ;

Reingold, Arthur ;

Thomas, Ann ;

Glode, Mary P. ;

Zell, Elizabeth R. ;

Jorgensen, James H. ;

Beall, Bernard ;

Schuchat, Anne .

LANCET, 2006, 368 (9546) :1495-1502

[42]

*WHO, 2008, EX SUMM WHO HLTH CAN

[43]

*WHO EXP COMM BIOL, 2010, REC ASS QUAL SAF EFF

[44] Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) When Coadministered With Different Neisseria meningitidis Serogroup C Conjugate Vaccines [J].

Wysocki, Jacek ;

Tejedor, Juan C. ;

Grunert, Dutlef ;

Konior, Ryszard ;

Garcia-Sicilia, Jose ;

Knuf, Markus ;

Bernard, Laurence ;

Dieussaert, Ilse ;

Schuerman, Lode .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (04) :S77-S88

[45] Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers [J].

Yeh, Sylvia H. ;

Gurtman, Alejandra ;

Hurley, David C. ;

Block, Stan L. ;

Schwartz, Richard H. ;

Patterson, Scott ;

Jansen, Kathrin U. ;

Love, Jack ;

Gruber, William C. ;

Emini, Emilio A. ;

Scott, Daniel A. .

PEDIATRICS, 2010, 126 (03) :E493-E505

[46]

,, 2007, Weekly Epidemiological Record, V82, P93

← 1 2 3 4 5 →